{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:02:37Z","timestamp":1784646157014,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009620","name":"Gansu Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010111","name":"The 900th Hospital of Joint Logistic Support Force PLA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jphs.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:25:41Z","timestamp":1782404741000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic study of meropenem in patients with severe infections and Monte Carlo simulation of the efficacy under different dosing regimens"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5706-6835","authenticated-orcid":false,"given":"Yuan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jphs.2026.06.008_bib1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1039\/C7NP00029D","article-title":"Nonribosomal peptide synthetase biosynthetic clusters of ESKAPE pathogens","volume":"34","author":"Gulick","year":"2017","journal-title":"Nat Prod Rep"},{"issue":"9","key":"10.1016\/j.jphs.2026.06.008_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074937","article-title":"Time to intubation is associated with outcome in patients with community-acquired pneumonia","volume":"8","author":"Hraiech","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1378\/chest.09-1547","article-title":"Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality","volume":"137","author":"Restrepo","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1378\/chest.07-1456","article-title":"A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU","volume":"133","author":"Restrepo","year":"2008","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jphs.2026.06.008_bib5","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/AAC.04166-14","article-title":"Population pharmacokinetics and monte carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units","volume":"59","author":"Jaruratanasirikul","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dku429","article-title":"Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations","volume":"70","author":"Ramon-Lopez","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jphs.2026.06.008_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40266-016-0431-9","article-title":"Meropenem dosing based on a population pharmacokinetic-pharmacodynamic model in elderly patients with infection of the lower respiratory tract","volume":"34","author":"Zhou","year":"2017","journal-title":"Drugs Aging"},{"issue":"6","key":"10.1016\/j.jphs.2026.06.008_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2005.08.015","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem","volume":"26","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jphs.2026.06.008_bib9","first-page":"276","article-title":"Population pharmacokinetics and pharmacodynamic target Attainment of meropenem in critically ill young children","volume":"22","author":"Cies","year":"2017","journal-title":"J Pediatr Pharmacol Therapeut"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00228-016-2172-4","article-title":"Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function","volume":"73","author":"Usman","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.jphs.2026.06.008_bib11","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1128\/AAC.00531-16","article-title":"Effect of obesity on the population pharmacokinetics of Meropenem in critically ill patients","volume":"60","author":"Alobaid","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jphs.2026.06.008_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02390-17","article-title":"Population pharmacokinetics of Meropenem in plasma and subcutis from patients on extracorporeal membrane oxygenation treatment","volume":"62","author":"Hanberg","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jphs.2026.06.008_bib13","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jphs.2026.06.008_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.jphs.2026.06.008_bib15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s11095-016-1856-x","article-title":"Simulation-based evaluation of PK\/PD indices for Meropenem across patient groups and experimental designs","volume":"33","author":"Kristoffersson","year":"2016","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.jphs.2026.06.008_bib16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jphs.2026.06.008_bib17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00228-019-02716-y","article-title":"Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte carlo simulation","volume":"75","author":"Idoate Grijalba","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2026.06.008_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","article-title":"Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study","volume":"21","author":"Ehmann","year":"2017","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s43440-020-00104-3","article-title":"Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial","volume":"72","author":"Onichimowski","year":"2020","journal-title":"Pharmacol Rep"},{"issue":"10","key":"10.1016\/j.jphs.2026.06.008_bib20","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/jac\/dkaa275","article-title":"A meropenem pharmacokinetics model in patients with haematological malignancies","volume":"75","author":"Contejean","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jphs.2026.06.008_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/dkx330","article-title":"Maximally effective dosing regimens of meropenem in patients with septic shock","volume":"73","author":"Sj\u00f6vall","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jphs.2026.06.008_bib22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijantimicag.2016.08.015","article-title":"Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis","volume":"48","author":"Tsai","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jphs.2026.06.008_bib23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-Lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib24","first-page":"190","article-title":"Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study","volume":"16","author":"Langan","year":"2014","journal-title":"Crit Care Resusc"},{"issue":"9","key":"10.1016\/j.jphs.2026.06.008_bib25","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1128\/AAC.42.9.2421","article-title":"Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration","volume":"42","author":"Krueger","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jphs.2026.06.008_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199528040-00002","article-title":"Clinical pharmacokinetics of meropenem","volume":"28","author":"Nicolau","year":"1995","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.jphs.2026.06.008_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00845-22","article-title":"Population Pharmacokinetics\/pharmacodynamics and clinical outcomes of Meropenem in critically ill patients","volume":"66","author":"Boonpeng","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jphs.2026.06.008_bib28","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.xphs.2022.01.015","article-title":"Population pharmacokinetics analysis and dosing simulations of Meropenem in critically ill patients with pulmonary infection","volume":"111","author":"Lan","year":"2022","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.jphs.2026.06.008_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jphs.2026.06.008_bib30","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jac\/dkx526","article-title":"Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model","volume":"73","author":"Minichmayr","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijantimicag.2019.06.016","article-title":"Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic\/pharmacodynamic analysis","volume":"54","author":"Ehmann","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jphs.2026.06.008_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IDR.S343264","article-title":"Meropenem target Attainment and population pharmacokinetics in critically ill septic patients with preserved or increased renal function","volume":"15","author":"Gijsen","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10.1016\/j.jphs.2026.06.008_bib33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.jphs.2026.06.008_bib34","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1093\/jac\/dkw200","article-title":"Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence","volume":"71","author":"Crandon","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jphs.2026.06.008_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1E271","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia","volume":"39","author":"Ariano","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jphs.2026.06.008_bib36","series-title":"Pharmacometric Approaches to Assess Antibiotic Dosing in Special Patient Populations: Towards Therapeutic Decision Support","year":"2019"},{"issue":"2","key":"10.1016\/j.jphs.2026.06.008_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3947\/ic.2016.48.2.81","article-title":"Prolonged versus intermittent infusion of \u03b2-Lactams for the treatment of nosocomial pneumonia: a meta-analysis","volume":"48","author":"Lal","year":"2016","journal-title":"Infect Chemother"},{"issue":"1","key":"10.1016\/j.jphs.2026.06.008_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jphs.2026.06.008_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02055-17","article-title":"Optimization of a meropenem-tobramycin combination dosage regimen against hypermutable and nonhypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model","volume":"62","author":"Landersdorfer","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jphs.2026.06.008_bib40","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.06389-11","article-title":"Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock","volume":"56","author":"Taccone","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jphs.2026.06.008_bib41","article-title":"Stability of meropenem after reconstitution for administration by prolonged infusion","volume":"14","author":"G\u00f3mez","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jphs.2026.06.008_bib42","first-page":"1569","article-title":"Clinical pharmacokinetics of meropenem in critically ill patients","volume":"58","author":"Lipman","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.jphs.2026.06.008_bib43","first-page":"1302","article-title":"Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis","volume":"80","author":"De Waele","year":"2014","journal-title":"Minerva Anestesiol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132600037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132600037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:19:07Z","timestamp":1784643547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134786132600037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S134786132600037X"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2026.06.008","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic study of meropenem in patients with severe infections and Monte Carlo simulation of the efficacy under different dosing regimens","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}